Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
41 hedge funds and large institutions have $21.1M invested in Kezar Life Sciences in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 14 reducing their positions, and 6 closing their positions.
5,700% more call options, than puts
Call options by funds: $58K | Put options by funds: $1K
1.66% more ownership
Funds ownership: 57.55% → 59.21% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 43 → 41 (-2)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
25% less capital invested
Capital invested by funds: $28.2M → $21.1M (-$7.11M)
50% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$2.18M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$249K |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$155K |
| 4 |
Squarepoint
New York
|
+$123K |
| 5 |
CHAM
Clear Harbor Asset Management
Stamford,
Connecticut
|
+$95.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAA
Affinity Asset Advisors
New York
|
-$956K |
| 2 |
Two Sigma Advisers
New York
|
-$216K |
| 3 |
Two Sigma Investments
New York
|
-$183K |
| 4 |
Goldman Sachs
New York
|
-$146K |
| 5 |
MAM
Marquette Asset Management
Minneapolis,
Minnesota
|
-$120K |
KZR Hedge Fund Activity: Q1 2025 in Review
41 of the 7,476 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q1 2025, worth a combined $21.1M — down 25% from $28.2M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of KZR and 5 opened new positions — a net loss of 1 holder — while 14 trimmed existing stakes and 7 added.
The largest buyer was BML Capital Management, adding an estimated $2.18M. The largest seller was Affinity Asset Advisors, exiting entirely with an estimated $956K sold.
- 41 institutional investors held Kezar Life Sciences (KZR) as of Q1 2025, down from 43 in Q4 2024.
- Funds reported $21.1M of Kezar Life Sciences stock for Q1 2025, down 25% quarter-over-quarter.
- 5 funds opened new Kezar Life Sciences positions in Q1 2025 and 6 closed out, a net change of -1 holder.
- The largest Kezar Life Sciences buyer in Q1 2025 was BML Capital Management, an estimated $2.18M added.
- The largest Kezar Life Sciences seller in Q1 2025 was Affinity Asset Advisors, an estimated $956K sold.
Based on aggregated 13F filings for Q1 2025.